Published in Medical Letter on the CDC and FDA, June 6th, 2010
"Although methicillin-resistant Staphylococcus aureus has been the most prominent target in the clinical development of daptomycin, this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.